Table 2.
COVID-19 vaccines patents/applications filed by key players.
| Patent/application number (Date of patent/publication) |
Summary of claims | Ref. No. |
|---|---|---|
| Moderna | ||
| US10703789B2 (July 7, 2020) |
A pharmaceutical composition (vaccine) comprising lipid nanoparticles containing an mRNA encoding a polypeptide that can be used as a vaccine. | [78] |
| US10702600B1 (July 7, 2020) |
A vaccine composition comprising a mRNA containing an open reading frame encoding a beta-coronavirus (Beta-CoV) S protein or S protein subunit formulated in a lipid nanoparticle. | [79] |
| US10064959B2 (September 4, 2018) |
A synthetic mRNA, which is effective as a vaccine when administered to a mammalian subject. | [80] |
| US10933127B2 (March 2, 2021) |
A method of inducing an immune response to the Beta-CoV S protein or S protein subunit in a mammal using a mRNA containing an open reading frame encoding a Beta-CoV S protein or S protein subunit formulated in a lipid nanoparticle in an effective amount. | [81] |
| BioNTech | ||
| US20190321458A1 (October 24, 2019) |
A vaccine composition comprising a single-stranded RNA containing an open reading frame encoding a peptide or protein of interest, and polyalkyleneimine (polyethylenimine and/or polypropylenimine). | [82] |
| US10729785B2 (August 4, 2020) |
A method of immunity stimulation against an infectious disease using a vaccine composition comprising protamine 1000/5000, a mRNA, and at least one endosome destabilizing agent. | [83] |
| Curevac | ||
| WO2021123332A1 (June 24, 2021) |
A method of treatment or prophylaxis of infectious diseases (COVID-19) using a vaccine of mRNA. | [84] |
| US20210023199A1 (January 28, 2021) |
A method of stimulating an antigen-specific immune response in a human subject comprising administering to the subject an effective amount of a vaccine composition containing a mRNA encoding a spike protein (S) from a SARS-CoV. | [85] |
| US20210060175A1 (March 4, 2021) |
A method of stimulating an immune response in a subject comprising administering an effective amount of a vaccine composition comprising a purified mRNA encoding a SARS-CoV antigen to the subject. | [86] |
| Janssen Pharmaceuticals | ||
| WO2021155323A1 (August 5, 2021) |
A vaccine against COVID-19 to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older, comprising a recombinant human adenovirus of serotype 26 that contains nucleic acid encoding a SARS-CoV-2 S protein or fragment thereof. | [87] |
| CA3101131A1 (July 31, 2021) |
A vaccine comprising a recombinant human adenovirus of serotype 26 that comprises a nucleic acid encoding a SARS-CoV-2 S protein. | [88] |
| Inovio Pharmaceuticals | ||
| US10548971B2 (February 4, 2020) |
An immunogenic vaccine composition comprising a nucleic acid molecule of a specific sequence for inducing an immune response against a coronavirus infection. | [89] |
| Gamaleya | ||
| EA037297B1 (March 5, 2021) |
A pharmaceutical agent of specific sequence ID for the induction of specific immunity against SARS-CoV-2. | [90] |
| EA037291B1 (March 5, 2021) |
An expression vector containing the genome of the recombinant human adenovirus to create an immunobiological agent for the induction of specific immunity against SARS-CoV-2. | [91] |
| RU2731342C1 (September 1, 2020) |
A pharmaceutical agent of specified sequence ID for the induction of specific immunity against SARS-CoV-2. | [92] |
| Novavax | ||
| WO2021154812A1 (August 5, 2021) |
A vaccine composition comprising coronavirus Spike glycoprotein of specific sequence ID to stimulate an immune response against SAR.S-CoV-2 in a subject. | [93] |
| US10953089B1 (March 23, 2021) |
An immunogenic vaccine composition comprising a nanoparticle containing a coronavirus S glycoprotein having a specific amino acid sequence. | [94] |